Microbot Medical Inc. announced it had successfully completed the Electromagnetic compatibility (EMC) testing section of the Verification and Validation (V&V) process. V&V are distinct procedures employed to ensure that a product, service, or system, aligns with specified requirements and effectively serves its intended purpose. The V&V, together with the pre-clinical pivotal study Microbot recently completed, are essential elements to an Investigational Device Exemption (IDE) submission for the FDA to commence clinical trials as part of the pathway for and receiving the required regulatory clearance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.88 USD | +1.95% | +1.73% | -46.34% |
Apr. 16 | HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating | MT |
Mar. 27 | Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.34% | 12.67M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process